In one of the Phase I clinical trials, individuals with relapsed/refractory NSCLC and positive for EGFR, were administered EGFR-CAR-T cell therapy and showed good tolerance to the treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.